Innovative Drug Pipeline InMed Pharmaceuticals is actively developing proprietary small molecule drug candidates targeting CB1 and CB2 receptors, with a focus on high unmet medical needs such as Alzheimer’s, ocular, and dermatological conditions. This presents opportunities to collaborate on advanced drug delivery systems or associated healthcare solutions.

Strong Industry Focus Positioned within the biotechnology research sector, InMed’s specialization in cannabinoid-based therapeutics and rare cannabinoids positions it as a key partner for companies seeking expertise in innovative cannabinoid formulations or supply chain solutions for niche markets.

Recent Strategic Developments The company is actively expanding its leadership and advisory teams with recent appointments of experienced directors and scientific advisors, signaling growth and increased focus on research & development. This opens avenues for strategic partnerships, joint ventures, or consulting opportunities.

Funding and Investment With recent plans to secure around CAD 10 million in funding, InMed is positioning itself for further clinical development and commercialization efforts. This presents potential sales opportunities in pharmaceutical manufacturing, clinical services, or commercialization support.

Market Engagements Participation in notable industry conferences such as AAIC and Emerging Growth Conferences demonstrates active market engagement and visibility within the biotech and pharmaceutical sectors, offering avenues for networking, partnership outreach, and platform-based sales opportunities.